Novartis AG’s (NVS -1.46 %) new heart-failure treatment should cost about 17% less than what the company is charging in the U.S. because wide use of the drug would strain […]

The Food and Drug Administration strengthened its safety warnings about heart-attack and stroke risks linked to a class of common pain relievers that includes medicines such as Celebrex, Advil, Motrin […]

It used to be that the major hurdle in getting a new drug approved was successfully completing phase 3 trials – the long-term studies needed to prove to regulators that […]

Entresto, Novartis’s novel heart failure (HF) drug, gained FDA approval earlier today. The approval arrived six weeks ahead of the drug’s action date. Formerly known as LCZ 696, the drug had already received […]